Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes – a simulation with the Diabetes Mellitus Model (DMM)

2007 ◽  
Vol 45 (12) ◽  
pp. 623-630 ◽  
Author(s):  
H.U. Janka ◽  
F. Hessel ◽  
S. Walzer ◽  
E. Müller
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Oral Antidiabetic Agents ◽  
Antidiabetic Agents ◽  
Oral Antidiabetic

DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa, in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents

2016 ◽  
Vol 13 (4) ◽  
Author(s):  
Askandar Tjokroprawiro ◽  
Sri Murtiwi ◽  
Raymond R. Tjandrawinata
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Prospective Clinical Study ◽  
Oral Antidiabetic Agents ◽  
Antidiabetic Agents ◽  
Oral Antidiabetic ◽  
Enhance Insulin Sensitivity ◽  
Bioactive Fraction

AbstractBackgroundDLBS3233, a combined bioactive fraction ofMethodsThis was an open and prospective clinical study for 12 weeks of therapy, involving type-2 diabetes mellitus patients who had been treated with two oral antidiabetic agents for at least 3 months prior to screening, yet, with HbAResultsAfter 12 weeks of treatment, the HbAConclusionsThe add-on oral antidiabetes therapy with DLBS3233 at the dose of 100 mg once daily helped type-2 diabetes mellitus patients to improve their glycemic control, enhance insulin sensitivity, lipid profile, and adiponectin level. In addition, DLBS3233 treatment concomitantly with other oral antidiabetic agents was proven safe and tolerable in type-2 diabetes subjects.

Sign in / Sign up

Export Citation Format

Share Document